New Strain of Antibiotic-Resistant E. coli Proves No Match for eradic8 A2Z!
2nd November 2007
In light of increased media and public interest in ESBL-producing E. coli, Amazon Bio-Guard decided to prove that their products could inactivate this potentially fatal strain of E. coli.
E. coli is a very common bacterium that normally lives harmlessly in the gut. However, certain strains produce an enzyme called extended-spectrum beta lactamase (ESBL), which makes them more resistant to cephalosporin antibiotics, subsequently making the infections harder to treat. Infections caused by ESBL-producing E. coli are a growing worldwide phenomenon and are not unique to the UK.
The Health Protection Agency (HPA) is one of the leading institutions worldwide in terms of research into this area and has been providing advice about these infections for many years, and subsequently produced a report on the increasing frequency of these infections in 2005. A lot of research still needs to be carried out into the origin of the strains of E. coli that cause infections. Imported chicken has been suggested as a possible route for their introduction into the UK. However, recent HPA research shows that the particular strains of E. coli and the particular ESBLs that they produce are significantly different from those so far found in chickens, so this link remains unproven.
ABG instructed their UK independent microbiological consultants, MGS Laboratories Ltd in Egham, Surrey, to source the culture and perform the tests to see if eradic8 A2Z demonstrated bactericidal efficacy against the organism. MGS Labs had not conducted any previous tests against this strain of E.coli so we are led to believe we are ahead of the game with our results!
Carried out to BS EN1276 disinfectant standard testing eradic8 A2Z performed extremely well, demonstrating a high level of efficacy against E. coli ESBL at a very low ready to use (RTU) dilution in the standard 5 minute contact time. For copies of this result or any of Amazon Bio-Guard’s results please contact us via the contacts page of this website.
